---
schema_version: "secwatch.filing_event.v1"
accession: "0001005286-24-000041"
form_type: "8-K"
ticker: "LFCR"
cik: "0001005286"
company_name: "LIFECORE BIOMEDICAL, INC. DE"
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:18:36.770414+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "medium"
source: SEC EDGAR
---

# Lifecore provides FY2024 guidance: rev $125M-$130M; 9M rev $90.5M (+25% YoY)

## Summary
- Nine-month revenue through Feb 24, 2024: $90.5M vs restated $72.1M in prior year, up 26%.
- Full-year FY2024 guidance: revenue $125M-$130M, adjusted EBITDA $13.5M-$16.9M.
- Development portfolio grows to 33 projects (+4 YoY); prospective pipeline has 68 opportunities.
- Capacity expansion: theoretical capacity to triple to ~70M units by FY2027; 5-head filler GMP-ready Aug 2024.
- Alcon HA supply agreement: capacity up 38% in FY2024; further 20% yield improvement expected in FY2025.

## SEC filing metadata
- accession: 0001005286-24-000041
- form_type: 8-K
- ticker: LFCR
- cik: 0001005286
- company_name: LIFECORE BIOMEDICAL, INC. DE
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1005286/000100528624000041/0001005286-24-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1005286/000100528624000041/lndc-20240401.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001005286-24-000041
- JSON: https://secwatch.observer/filing/0001005286-24-000041.json
- Plain text: https://secwatch.observer/filing/0001005286-24-000041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.